When is 4160's latest earnings report released?
The most recent financial report for 訊聯基因 (4160) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4160's short-term business performance and financial health. For the latest updates on 4160's earnings releases, visit this page regularly.
Where does 4160 fall in the P/E River chart?
According to historical valuation range analysis, 訊聯基因 (4160)'s current price-to-earnings (P/E) ratio is 88.97, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of 4160?
According to the latest financial report, 訊聯基因 (4160) reported an Operating Profit of -3.46M with an Operating Margin of -2.38% this period, representing a decline of 119.83% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is 4160's revenue growth?
In the latest financial report, 訊聯基因 (4160) announced revenue of 145.46M, with a Year-Over-Year growth rate of -14.51%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does 4160 have?
At the end of the period, 訊聯基因 (4160) held Total Cash and Cash Equivalents of 75.19M, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does 4160 go with three margins increasing?
In the latest report, 訊聯基因 (4160) did not achieve the “three margins increasing” benchmark, with a gross margin of 40.4%%, operating margin of -2.38%%, and net margin of 0.31%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4160's profit trajectory and future growth potential.
Is 4160's EPS continuing to grow?
According to the past four quarterly reports, 訊聯基因 (4160)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of 4160?
訊聯基因 (4160)'s Free Cash Flow (FCF) for the period is -37.18M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 158.62% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
